In August 2023, FDA approved Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age to prevent lower respiratory tract disease (LRTD), including severe LRTD, caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. A pragmatic approach to narrow the interval of use of Abrysvo in pregnant individuals balanced benefits of vaccine effectiveness against potential risks to infant and mother.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528063 | PMC |
http://dx.doi.org/10.1038/s41541-024-01002-y | DOI Listing |
Rev Bras Enferm
January 2025
Universidade Federal de Minas Gerais. Belo Horizonte, Minas Gerais, Brazil.
Objective: To analyze the determinants for non-vaccination against COVID-19 in pregnant women in Belo Horizonte, Minas Gerais, Brazil.
Methods: An epidemiological study with a cross-sectional design was conducted using data from the project titled "Childbirth and Breastfeeding in Children of Mothers Infected by SARS-CoV-2," developed during the pandemic in the city of Belo Horizonte, Minas Gerais, Brazil.
Results: The study sample consisted of 360 pregnant women, of whom 77.
J Acquir Immune Defic Syndr
November 2024
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA.
Background: Limited data exist on bictegravir pharmacokinetics in pregnancy among persons with HIV (PWH) and infant washout.
Setting: Nonrandomized, open-label, multi-center phase-IV prospective study of bictegravir pharmacokinetics and safety in pregnant PWH and their infants.
Methods: Steady-state 24-hour pharmacokinetic sampling of oral bictegravir 50 mg once daily (a component of fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide) during the 2nd and 3rd trimesters and postpartum was performed.
PLOS Glob Public Health
January 2025
Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.
Vertical transmission of HIV continues to be a key contributor to pediatric HIV infections globally. Routine HIV testing at each antenatal care (ANC) visit can reduce the likelihood of such infections. However, a sub-optimal number of women are re-tested for HIV on their subsequent ANC visits.
View Article and Find Full Text PDFPLoS One
January 2025
Duke Center for Policy Impact in Global Health, Durham, North Carolina, United States of America.
Background: Hypertension is the most common primary diagnosis associated with postpartum readmissions within 42 days of delivery hospitalization. In the United States, nearly half of the cases of eclampsia, a severe form of preeclampsia, develop during the postpartum period, and the postpartum onset of hypertensive disorders of pregnancy, like antepartum hypertension poses long-term health risks to pregnant individuals, including an increased likelihood of developing overall cardiovascular disease, coronary heart disease, heart failure, and chronic hypertension. In this paper, we estimate the trends in the incidence of readmissions for postpartum hypertension within 42 days of delivery discharge in the US, disaggregated by median household income.
View Article and Find Full Text PDFJ Ethn Subst Abuse
January 2025
Centre of Research Excellence: Indigenous Sovereignty & Smoking, Auckland, New Zealand.
Maternal smoking increases adverse risks for both the mother's pregnancy and the unborn child and remains disproportionately high among some Indigenous peoples. Decreasing smoking among pregnant Indigenous women has been identified as a health priority in New Zealand because of wide inequities in smoking-related harms. Using pre- and post-intervention questionnaires, this feasibility study assessed the acceptability and potential efficacy of a novel cessation program designed for Indigenous women by Indigenous experts utilizing traditional knowledge and practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!